dr. giorgio scagliotti discusses afatinib in patients with egfr mutation
Published 10 years ago • 216 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
1:16
dr. scagliotti on treating egfr-mutated tumors with afatinib
-
4:06
afatinib in patients with uncommon egfr mutations
-
1:37
dr. scagliotti discusses egfr mutations in nsclc
-
0:54
dr. scagliotti on egfr targeted therapy survival benefits
-
5:20
ilk lenfome olduğumu nasıl öğrendim!
-
12:03
lenfoma nedir? ne zaman lenfomadan şüphelenilir? // doç. dr. hilmi doğu
-
8:12
francesca ferrua
-
0:55
dr. giorgio scagliotti on combining targeted therapies with chemotherapy
-
1:35
dr. bunn discusses afatinib for patients with egfr mutation
-
1:47
dr. scagliotti on mechanisms of resistance to egfr tkis
-
1:32
dr. scagliotti discusses elderly lung cancer therapy
-
1:00
dr. scagliotti discusses the future of lung cancer therapy
-
1:49
dr. scagliotti on toxicities related to surgery and chemotherapy in patients with lung cancer
-
15:43
prof. georgio scagliotti, md, phd: lung cancer mutations and the future of treatment
-
1:00
idr. giorgio scagliotti on taking a targeted approach to immunotherapy in lung cancer
-
2:20
osimertinib with chemotherapy in egfr-mutated nsclc | nejm
-
1:59
dr. scagliotti on lung cancer treatment-related toxicities
-
1:49
adjuvant osimertinib and advanced egfr-mutated nsclc | nejm
-
1:17
dr. scagliotti gives 3 important lung cancer takeaway points
-
5:26
first-line osimertinib in egfr mutant ansclc patients: progression pattern and safety in the rea...
-
1:47
dr. west on fda approval of afatinib in nsclc with rare egfr mutations
-
3:39
dr. scagliotti reviews recent findings on molecular genotyping in lung cancer